Sökning: WFRF:(Brennen W. Nathaniel) >
Tasquinimod Is an A...
Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
-
Isaacs, John T. (författare)
-
Antony, Lizamma (författare)
-
Dalrymple, Susan L. (författare)
-
visa fler...
-
Brennen, W. Nathaniel (författare)
-
Gerber, Stephanie (författare)
-
Hammers, Hans (författare)
-
Wissing, Michel (författare)
-
Kachhap, Sushant (författare)
-
Luo, Jun (författare)
-
Xing, Li (författare)
-
Bjork, Per (författare)
-
Olsson, Anders (författare)
-
Bjork, Anders (författare)
-
- Leanderson, Tomas (författare)
- Lund University,Lunds universitet,Immunologi,Forskargrupper vid Lunds universitet,Immunology,Lund University Research Groups
-
visa färre...
-
(creator_code:org_t)
- 2013
- 2013
- Engelska.
-
Ingår i: Cancer Research. - 1538-7445. ; 74:4, s. 1386-1399
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Tasquinimod is an orally active antiangiogenic drug that is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer. However, the target of this drug has remained unclear. In this study, we applied diverse strategies to identify the histone deacetylase HDAC4 as a target for the antiangiogenic activity of tasquinimod. Our comprehensive analysis revealed allosteric binding (Kd 10-30 nmol/L) to the regulatory Zn2+ binding domain of HDAC4 that locks the protein in a conformation preventing HDAC4/N-CoR/HDAC3 complex formation. This binding inhibited colocalization of N-CoR/HDAC3, thereby inhibiting deacetylation of histones and HDAC4 client transcription factors, such as HIF-1 alpha, which are bound at promoter/enhancers where epigenetic reprogramming is required for cancer cell survival and angiogenic response. Through this mechanism, tasquinimod is effective as a monotherapeutic agent against human prostate, breast, bladder, and colon tumor xenografts, where its efficacy could be further enhanced in combination with a targeted thapsigargin prodrug (G202) that selectively kills tumor endothelial cells. Together, our findings define a mechanism of action of tasquinimod and offer a perspective on how its clinical activity might be leveraged in combination with other drugs that target the tumor microenvironment. Cancer Res; 73(4); 1386-99. (C) 2012 AACR.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Isaacs, John T.
-
Antony, Lizamma
-
Dalrymple, Susan ...
-
Brennen, W. Nath ...
-
Gerber, Stephani ...
-
Hammers, Hans
-
visa fler...
-
Wissing, Michel
-
Kachhap, Sushant
-
Luo, Jun
-
Xing, Li
-
Bjork, Per
-
Olsson, Anders
-
Bjork, Anders
-
Leanderson, Toma ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Immunologi inom ...
- Artiklar i publikationen
-
Cancer Research
- Av lärosätet
-
Lunds universitet